{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:06:26Z","timestamp":1784739986402,"version":"3.55.0"},"reference-count":337,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T00:00:00Z","timestamp":1464220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"ARRS","doi-asserted-by":"publisher","award":["P3-0171"],"award-info":[{"award-number":["P3-0171"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Alzheimer\u2019s disease (AD) is the most common form of dementia, with a prevalence that increases with age. By 2050, the worldwide number of patients with AD is projected to reach more than 140 million. The prominent signs of AD are progressive memory loss, accompanied by a gradual decline in cognitive function and premature death. AD is the clinical manifestation of altered proteostasis. The initiating step of altered proteostasis in most AD patients is not known. The progression of AD is accelerated by several chronic disorders, among which the contribution of diabetes to AD is well understood at the cell biology level. The pathological mechanisms of AD and diabetes interact and tend to reinforce each other, thus accelerating cognitive impairment. At present, only symptomatic interventions are available for treating AD. To optimise symptomatic treatment, a personalised therapy approach has been suggested. Intranasal insulin administration seems to open the possibility for a safe, and at least in the short term, effective symptomatic intervention that delays loss of cognition in AD patients. This review summarizes the interactions of AD and diabetes from the cell biology to the patient level and the clinical results of intranasal insulin treatment of cognitive decline in AD.<\/jats:p>","DOI":"10.3390\/molecules21060689","type":"journal-article","created":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T12:13:20Z","timestamp":1464264800000},"page":"689","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The Rationale for Insulin Therapy in Alzheimer\u2019s Disease"],"prefix":"10.3390","volume":"21","author":[{"given":"Samo","family":"Ribari\u010d","sequence":"first","affiliation":[{"name":"Institute of Pathophysiology, Faculty of Medicine, University of Ljubljana, Zalo\u0161ka 4, SI-1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2016,5,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.neubiorev.2009.05.006","article-title":"Alzheimer\u2019s disease and blood-brain barrier function\u2014Why have anti-beta-amyloid therapies failed to prevent dementia progression?","volume":"33","author":"Pahnke","year":"2009","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMra0909142","article-title":"Alzheimer\u2019s disease","volume":"362","author":"Querfurth","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.brainres.2011.12.063","article-title":"Insulin signaling, glucose metabolism and mitochondria: Major players in Alzheimer\u2019s disease and diabetes interrelation","volume":"1441","author":"Correia","year":"2012","journal-title":"Brain Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40263-013-0076-8","article-title":"Intranasal insulin as a treatment for Alzheimer\u2019s disease: A review of basic research and clinical evidence","volume":"27","author":"Freiherr","year":"2013","journal-title":"CNS Drugs"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Vandal, M., Bourassa, P., and Calon, F. (2015). Can insulin signaling pathways be targeted to transport A\u03b2 out of the brain?. Front. Aging Neurosci., 7.","DOI":"10.3389\/fnagi.2015.00114"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.neuroscience.2013.07.009","article-title":"Molecular links between Alzheimer\u2019s disease and diabetes mellitus","volume":"250","author":"Yang","year":"2013","journal-title":"Neuroscience"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pneurobio.2013.06.004","article-title":"Decoding Alzheimer\u2019s disease from perturbed cerebral glucose metabolism: Implications for diagnostic and therapeutic strategies","volume":"108","author":"Chen","year":"2013","journal-title":"Prog. Neurobiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/978-1-4419-8969-7_8","article-title":"Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: Therapeutic implications","volume":"541","author":"Hoyer","year":"2004","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/archneurol.2007.29","article-title":"Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: The Cardiovascular Health Study Cognition Study","volume":"65","author":"Irie","year":"2008","journal-title":"Arch. Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.7326\/0003-4819-137-3-200208060-00006","article-title":"Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease","volume":"137","author":"Kivipelto","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1001\/archneur.64.4.570","article-title":"Relation of diabetes to mild cognitive impairment","volume":"64","author":"Luchsinger","year":"2007","journal-title":"Arch. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1212\/WNL.53.9.1937","article-title":"Diabetes mellitus and the risk of dementia: The Rotterdam Study","volume":"53","author":"Ott","year":"1999","journal-title":"Neurology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0361-9230(03)00067-4","article-title":"Causative and susceptibility genes for Alzheimer\u2019s disease: A review","volume":"61","author":"Rocchi","year":"2003","journal-title":"Brain Res. Bull."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030","volume":"27","author":"Wild","year":"2004","journal-title":"Diabetes Care"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.bcp.2013.12.012","article-title":"Brain metabolic dysfunction at the core of Alzheimer\u2019s disease","volume":"88","author":"Tong","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/dmrr.632","article-title":"Cognitive dysfunction associates with whitematter hyperintensities and subcortical atrophy onmagnetic resonance imaging of the elderly diabetes mellitus Japanese elderly diabetes intervention trial (J-EDIT)","volume":"22","author":"Akisaki","year":"2006","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1007\/s00125-003-1235-0","article-title":"Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI","volume":"46","author":"Vermeer","year":"2003","journal-title":"Diabetologia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.2337\/diabetes.55.04.06.db05-1323","article-title":"Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes","volume":"55","author":"Manschot","year":"2006","journal-title":"Diabetes"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2337\/diabetes.53.3.687","article-title":"Magnetic resonance imaging of the brain in diabetes: The Cardiovascular Determinants of Dementia (CASCADE) Study","volume":"53","author":"Schmidt","year":"2004","journal-title":"Diabetes"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2174\/156652407783220705","article-title":"RAGE, diabetes, and the nervous system","volume":"7","author":"Toth","year":"2007","journal-title":"Curr. Mol. Med."},{"key":"ref_22","first-page":"373","article-title":"The relationship between Alzheimer\u2019s disease and diabetes: Type 3 diabetes?","volume":"14","author":"Kroner","year":"2009","journal-title":"Altern. Med. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"474","DOI":"10.2337\/diabetes.53.2.474","article-title":"Increased risk of type 2 diabetes in Alzheimer disease","volume":"53","author":"Janson","year":"2004","journal-title":"Diabetes"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1262-3636(07)70298-7","article-title":"Diabetes mellitus and dementia","volume":"32","author":"Pasquier","year":"2006","journal-title":"Diabetes Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbadis.2008.08.005","article-title":"Human cerebral neuropathology of Type 2 diabetes mellitus","volume":"1792","author":"Nelson","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3233\/JAD-2009-0984","article-title":"Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis","volume":"16","author":"Lawton","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.neurobiolaging.2005.09.003","article-title":"Studies of the effects of high fat diets on cognitive function in a rat model","volume":"26","author":"Winocur","year":"2005","journal-title":"Neurobiol. Aging"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Tong, M., Longato, L., and de la Monte, S.M. (2010). Early limited nitrosamine exposures exacerbate high fat diet-mediated type2 diabetes and neurodegeneration. BMC Endocr. Dis., 10.","DOI":"10.1186\/1472-6823-10-4"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev.biochem.75.101304.123901","article-title":"Protein misfolding, functional amyloid, and human disease","volume":"75","author":"Chiti","year":"2006","journal-title":"Annu. Rev. Biochem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"417","DOI":"10.18388\/abp.2005_3454","article-title":"Molecular mechanisms initiating amyloid beta-fibril formation in Alzheimer\u2019s disease","volume":"52","author":"Kirkitadze","year":"2005","journal-title":"Acta Biochim. Pol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease: Progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"A23","DOI":"10.1038\/399a023","article-title":"Translating cell biology into therapeutic advances in Alzheimer\u2019s disease","volume":"399","author":"Selkoe","year":"1999","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1439760","article-title":"Production of the Alzheimer amyloid beta protein by normal proteolytic processing","volume":"258","author":"Shoji","year":"1992","journal-title":"Science"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cell.2005.02.008","article-title":"Twenty years of the Alzheimer\u2019s disease amyloid hypothesis: A genetic perspective","volume":"120","author":"Tanzi","year":"2005","journal-title":"Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1126\/science.2218531","article-title":"Neurotropic and neurotoxic effects of amyloid b protein: Reversal by tachykinin neuropeptides","volume":"250","author":"Yankner","year":"1990","journal-title":"Science"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1021\/acschemneuro.5b00229","article-title":"Soluble Prion Protein Binds Isolated Low Molecular Weight Amyloid-\u03b2 Oligomers Causing Cytotoxicity Inhibition","volume":"6","author":"Williams","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0002-9440(10)65184-X","article-title":"Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer\u2019s disease","volume":"155","author":"Lue","year":"1999","journal-title":"Am. J. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M","article-title":"Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer\u2019s disease","volume":"46","author":"McLean","year":"1999","journal-title":"Ann. Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","article-title":"Diffusible, nonfibrillar ligands derived from Abeta1\u201342 are potent central nervous system neurotoxins","volume":"95","author":"Lambert","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm1782","article-title":"Amyloid-beta protein dimers isolated directly from Alzheimer\u2019s brains impair synaptic plasticity and memory","volume":"14","author":"Shankar","year":"2008","journal-title":"Nat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1113\/jphysiol.2005.103754","article-title":"Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: A potent role for trimers","volume":"572","author":"Townsend","year":"2006","journal-title":"J. Physiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0006-8993(01)03058-X","article-title":"Soluble oligomers of beta amyloid (1\u201342) inhibit long-term potentiation but not long-term depression in rat dentate gyrus","volume":"924","author":"Wang","year":"2002","journal-title":"Brain Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nn1372","article-title":"Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function","volume":"8","author":"Cleary","year":"2005","journal-title":"Nat. Neurosci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nature04533","article-title":"A specific amyloid-beta protein assembly in the brain impairs memory","volume":"440","author":"Lesne","year":"2006","journal-title":"Nature"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bbr.2008.06.001","article-title":"Oligomers of the amyloid-beta protein disrupt working memory: Confirmation with two behavioral procedures","volume":"193","author":"Poling","year":"2008","journal-title":"Behav. Brain Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1523\/JNEUROSCI.4970-06.2007","article-title":"Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway","volume":"27","author":"Shankar","year":"2007","journal-title":"J. Neurosci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"14077","DOI":"10.1074\/jbc.275.19.14077","article-title":"Alzheimer\u2019s beta-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line","volume":"275","author":"Kawahara","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"11338","DOI":"10.1021\/bi020314u","article-title":"Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes","volume":"41","author":"Anguiano","year":"2002","journal-title":"Biochemistry"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.febslet.2008.05.006","article-title":"Human but not rat amylin shares neurotoxic properties with Abeta42 in long-term hippocampal and cortical cultures","volume":"582","author":"Lim","year":"2008","journal-title":"FEBS Lett."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00125-003-1304-4","article-title":"Islet amyloid: A complication of islet dysfunction or an aetiological factor in Type 2 diabetes?","volume":"47","author":"Clark","year":"2004","journal-title":"Diabetologia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1210\/er.2007-0037","article-title":"Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis","volume":"29","author":"Haataja","year":"2008","journal-title":"Endocr. Rev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1210\/edrv-15-2-163","article-title":"Amylin compared with calcitonin gene-related peptide: Structure, biology, and relevance to metabolic disease","volume":"15","author":"Cooper","year":"1994","journal-title":"Endocr. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"12206","DOI":"10.1074\/jbc.M312452200","article-title":"Human amylin oligomer growth and fibril elongation define two distinct phases in amyloid formation","volume":"279","author":"Green","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"10971","DOI":"10.1021\/bi034889i","article-title":"The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies","volume":"42","author":"Porat","year":"2003","journal-title":"Biochemistry"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1126\/science.1079469","article-title":"Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis","volume":"300","author":"Kayed","year":"2003","journal-title":"Science"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"13505","DOI":"10.1021\/bi701427q","article-title":"Peptide conformation and supramolecular organization in amylin fibrils: Constraints from solid-state NMR","volume":"46","author":"Luca","year":"2007","journal-title":"Biochemistry"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2337\/diabetes.48.3.491","article-title":"The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles","volume":"48","author":"Janson","year":"1999","journal-title":"Diabetes"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1111\/j.1742-4658.2006.05367.x","article-title":"The aggregation potential of human amylin determines its cytotoxicity towards islet beta-cells","volume":"273","author":"Konarkowska","year":"2006","journal-title":"FEBS J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"E1317","DOI":"10.1152\/ajpendo.00082.2006","article-title":"Inhibition of human IAPP fibril formation does not prevent beta-cell death: Evidence for distinct actions of oligomers and fibrils of human IAPP","volume":"291","author":"Meier","year":"2006","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.2337\/db07-0197","article-title":"High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes","volume":"56","author":"Huang","year":"2007","journal-title":"Diabetes"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"46363","DOI":"10.1074\/jbc.C400260200","article-title":"Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases","volume":"279","author":"Kayed","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1074\/jbc.271.4.1988","article-title":"Pore formation by the cytotoxic islet amyloid peptide amylin","volume":"271","author":"Mirzabekov","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_63","first-page":"151","article-title":"Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: Quantitative changes in the pancreas in type 2 diabetes","volume":"9","author":"Clark","year":"1988","journal-title":"Diabetes Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2337\/diabetes.48.2.241","article-title":"Islet amyloid: A long-recognized but underappreciated pathological feature of type 2 diabetes","volume":"48","author":"Kahn","year":"1999","journal-title":"Diabetes"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1073\/pnas.87.13.5036","article-title":"Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation","volume":"87","author":"Westermark","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1210\/me.2004-0407","article-title":"Processing of pro-islet amyloid polypeptide in the constitutive and regulated secretory pathways of beta cells","volume":"19","author":"Marzban","year":"2005","journal-title":"Mol. Endocrinol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s001250051138","article-title":"Prolonged exposure of pancreatic beta cells to raised glucose concentrations results in increased cellular content of islet amyloid polypeptide precursors","volume":"42","author":"Hou","year":"1999","journal-title":"Diabetologia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.2337\/db05-1566","article-title":"Impaired NH2-terminal processing of human proislet amyloid polypeptide by the prohormone convertase PC2 leads to amyloid formation and cell death","volume":"55","author":"Marzban","year":"2006","journal-title":"Diabetes"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.2337\/diabetes.54.7.2117","article-title":"Aberrant processing of human proislet amyloid polypeptide results in increased amyloid formation","volume":"54","author":"Paulsson","year":"2005","journal-title":"Diabetes"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"7283","DOI":"10.1073\/pnas.93.14.7283","article-title":"Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide","volume":"93","author":"Janson","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1073\/pnas.93.8.3492","article-title":"Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide","volume":"93","author":"Verchere","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bbrc.2006.12.187","article-title":"Glucose- and time-dependence of islet amyloid formation in vitro","volume":"354","author":"Zraika","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s00125-008-1255-x","article-title":"Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloid-induced beta cell apoptosis","volume":"52","author":"Zraika","year":"2009","journal-title":"Diabetologia"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ana.23956","article-title":"Amylin deposition in the brain: A second amyloid in Alzheimer disease?","volume":"74","author":"Jackson","year":"2013","journal-title":"Ann. Neurol."},{"key":"ref_75","first-page":"9","article-title":"Neuroinflammation and neurologic deficits in diabetes linked to brain accumulation of amylin","volume":"22","author":"Srodulski","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/11597760-000000000-00000","article-title":"Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer\u2019s disease","volume":"72","year":"2012","journal-title":"Drugs"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neurobiolaging.2007.07.015","article-title":"Blood-brain barrier: Ageing and microvascular disease\u2013systematic review and meta-analysis","volume":"30","author":"Farrall","year":"2009","journal-title":"Neurobiol. Aging"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/jcbfm.2013.135","article-title":"Blood-brain barrier dysfunction as a cause and consequence of Alzheimer\u2019s disease","volume":"33","author":"Erickson","year":"2013","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"E1315","DOI":"10.1152\/ajpendo.00067.2014","article-title":"Glucose hypometabolism is highly localized, but lower cortical thickness and brain atrophy are widespread in cognitively normal older adults","volume":"306","author":"Nugent","year":"2014","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.neuron.2014.12.032","article-title":"Blood-brain barrier breakdown in the aging human hippocampus","volume":"85","author":"Montagne","year":"2015","journal-title":"Neuron"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/jmri.20669","article-title":"Vascular volume and blood-brain barrier permeability measured by dynamic contrast enhanced MRI in hippocampus and cerebellum of patients with MCI and normal controls","volume":"24","author":"Wang","year":"2006","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/mrm.22686","article-title":"Quantitative measurement of blood-brain barrier permeability in human using dynamic contrast-enhanced MRI with fast T1 mapping","volume":"65","author":"Taheri","year":"2011","journal-title":"Magn. Reson. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"a011452","DOI":"10.1101\/cshperspect.a011452","article-title":"Neurovascular dysfunction and faulty amyloid beta-peptide clearance in Alzheimer disease","volume":"2","author":"Sagare","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.neurobiolaging.2006.12.008","article-title":"Hippocampal hypometabolism predicts cognitive decline from normal aging","volume":"29","author":"Mosconi","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bbadis.2008.10.014","article-title":"Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer\u2019s disease","volume":"1792","author":"Zhao","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF01258634","article-title":"Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type","volume":"75","author":"Hoyer","year":"1989","journal-title":"J. Neural. Transm."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1073\/pnas.2635903100","article-title":"Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer\u2019s dementia","volume":"101","author":"Reiman","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.brainres.2007.08.063","article-title":"Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP\/PS1 mice","volume":"1181","author":"Hooijmans","year":"2007","journal-title":"Brain Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.febslet.2007.12.035","article-title":"Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease","volume":"582","author":"Liu","year":"2008","journal-title":"FEBS Lett."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Li, H., Guo, Q., Inoue, T., Polito, V.A., Tabuchi, K., Hammer, R.E., Pautler, R.G., Taffet, G.E., and Zheng, H. (2014). Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: Interplay with cerebral blood flow. Mol. Neurodegener., 9.","DOI":"10.1186\/1750-1326-9-28"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nm890","article-title":"RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain","volume":"9","author":"Deane","year":"2003","journal-title":"Nat. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/archneurol.2010.225","article-title":"Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes","volume":"68","author":"Baker","year":"2011","journal-title":"Arch. Neurol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1007\/s00125-014-3333-6","article-title":"Cerebrospinal fluid levels of Alzheimer\u2019s disease biomarkers in middle-aged patients with type 1 diabetes","volume":"57","author":"Ouwens","year":"2014","journal-title":"Diabetologia"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.neuropharm.2009.03.001","article-title":"Downregulation of LRP1 [correction of LPR1] at the blood-brain barrier in streptozotocin-induced diabetic mice","volume":"56","author":"Hong","year":"2009","journal-title":"Neuropharmacology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/jnr.23511","article-title":"Effects of insulin combined with idebenone on blood-brain barrier permeability in diabetic rats","volume":"93","author":"Sun","year":"2015","journal-title":"J. Neurosci. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/385343a0","article-title":"Regulation by insulin of a unique neuronal Ca2+ pool and of neuropeptide secretion","volume":"385","author":"Jonas","year":"1997","journal-title":"Nature"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/41792","article-title":"Recruitment of functional GABA(A) receptors to postsynaptic domains by insulin","volume":"388","author":"Wan","year":"1997","journal-title":"Nature"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0896-6273(00)81066-1","article-title":"Expression of cerebellar long-term depression requires postsynaptic clathrin-mediated endocytosis","volume":"25","author":"Wang","year":"2000","journal-title":"Neuron"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1073\/pnas.051634698","article-title":"Insulin promotes rapid delivery of N-methyl-d-aspartate receptors to the cell surface by exocytosis","volume":"98","author":"Skeberdis","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/sj.emboj.7600126","article-title":"Tyrosine phosphorylation of GluR2 is required for insulin-stimulated AMPA receptor endocytosis and LTD","volume":"23","author":"Ahmadian","year":"2004","journal-title":"EMBO J."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0303-7207(01)00455-5","article-title":"Role of insulin and insulin receptor in learning and memory","volume":"177","author":"Zhao","year":"2001","journal-title":"Mol. Cell Endocrinol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1517\/14728222.6.5.555","article-title":"The role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes","volume":"6","author":"Kaidanovich","year":"2002","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.diabres.2007.01.033","article-title":"The role of GSK3 in glucose homeostasis and the development of insulin resistance","volume":"77","author":"Lee","year":"2007","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1007\/s00018-005-5597-y","article-title":"Glycogen synthase kinase 3beta and Alzheimer\u2019s disease: Pathophysiological and therapeutic significance","volume":"63","author":"Balaraman","year":"2006","journal-title":"Cell Mol. Life Sci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"9632","DOI":"10.1523\/JNEUROSCI.2236-04.2004","article-title":"Brain insulin impairs amyloid-beta(1\u201340) clearance from the brain","volume":"24","author":"Shiiki","year":"2004","journal-title":"J. Neurosci."},{"key":"ref_106","first-page":"149","article-title":"Insulin-degrading enzyme","volume":"19","author":"Authier","year":"1996","journal-title":"Clin. Investig. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1523\/JNEUROSCI.20-05-01657.2000","article-title":"Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme","volume":"20","author":"Vekrellis","year":"2000","journal-title":"J. Neurosci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1073\/pnas.0230450100","article-title":"Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo","volume":"100","author":"Farris","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"11120","DOI":"10.1523\/JNEUROSCI.2860-04.2004","article-title":"Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: Implications for Alzheimer\u2019s disease intervention","volume":"24","author":"Zhao","year":"2004","journal-title":"J. Neurosci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"18742","DOI":"10.1074\/jbc.M109.011015","article-title":"Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric AB","volume":"284","author":"Zhao","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1073\/pnas.0809158106","article-title":"Protection of synapses against Alzheimer\u2019s-linked toxins: Insulin signaling prevents the pathogenic binding of Abeta oligomers","volume":"106","author":"Vieira","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_112","first-page":"S26","article-title":"How does brain insulin resistance develop in Alzheimer\u2019s disease?","volume":"10","author":"Lourenco","year":"2014","journal-title":"Alzheimers Dement."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/db13-1954","article-title":"Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease","volume":"63","author":"Ferreira","year":"2014","journal-title":"Diabetes"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1172\/JCI64595","article-title":"Alzheimer\u2019s disease and insulin resistance: Translating basic science into clinical applications","volume":"123","year":"2013","journal-title":"J. Clin. Invest."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.jalz.2013.12.010","article-title":"Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer\u2019s disease","volume":"10","author":"Ferreira","year":"2014","journal-title":"Alzheimers Dement."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/j.1471-4159.2007.05194.x","article-title":"The GSK3 hypothesis of Alzheimer\u2019s disease","volume":"104","author":"Hooper","year":"2008","journal-title":"J. Neurochem."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JAD-2008-13309","article-title":"Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults","volume":"13","author":"Reger","year":"2008","journal-title":"J. Alzheimers Dis."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1212\/WNL.50.1.164","article-title":"Cerebrospinal fluid and plasma insulin levels in Alzheimer\u2019s disease: Relationship to severity of dementia and apolipoprotein E genotype","volume":"50","author":"Craft","year":"1999","journal-title":"Neurology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3233\/JAD-2005-7107","article-title":"Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer\u2019s disease\u2014is this type 3 diabetes?","volume":"7","author":"Steen","year":"2005","journal-title":"J. Alzheimers Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3233\/JAD-2005-8304","article-title":"Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer\u2019s disease: Link to brain reductions in acetylcholine","volume":"8","author":"Rivera","year":"2005","journal-title":"J. Alzheimers Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0197-4580(95)02002-0","article-title":"Memory improvement following induced hyperinsulinemia in Alzheimer\u2019s disease","volume":"17","author":"Craft","year":"1996","journal-title":"Neurobiol. Aging"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1212\/01.WNL.0000265401.62434.36","article-title":"Intranasal insulin improves cognition and modulates beta-amyloid in early AD","volume":"70","author":"Reger","year":"2008","journal-title":"Neurology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"7084","DOI":"10.1523\/JNEUROSCI.23-18-07084.2003","article-title":"Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation","volume":"23","author":"Schubert","year":"2003","journal-title":"J. Neurosci."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1073\/pnas.0308724101","article-title":"Role for neuronal insulin resistance in neurodegenerative diseases","volume":"101","author":"Schubert","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1471-4159.2006.04368.x","article-title":"Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein","volume":"101","author":"Grunblatt","year":"2007","journal-title":"J. Neurochem."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/emboj\/20.1.27","article-title":"Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice","volume":"20","author":"Lucas","year":"2001","journal-title":"EMBOJ"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nature01640","article-title":"GSK-3alpha regulates production of Alzheimer\u2019s disease amyloid-beta peptides","volume":"423","author":"Phiel","year":"2003","journal-title":"Nature"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1073\/pnas.0500466102","article-title":"Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo","volume":"102","author":"Noble","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1084\/jem.20081588","article-title":"Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer\u2019s disease mouse models","volume":"205","author":"Qing","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1172\/JCI64516","article-title":"Inhibition of GSK3beta-mediated BACE1 expression reduces Alzheimer-associated phenotypes","volume":"123","author":"Ly","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3233\/JAD-2002-4504","article-title":"Amyloid beta antagonizes insulin promoted secretion of the amyloid beta protein precursor","volume":"4","author":"Ling","year":"2002","journal-title":"J. Alzheimers. Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1523\/JNEUROSCI.22-10-j0001.2002","article-title":"Alzheimer\u2019s beta-amyloid peptides compete for insulin binding to the insulin receptor","volume":"22","author":"Xie","year":"2002","journal-title":"J. Neurosci."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0006-8993(98)00510-1","article-title":"Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: Effects of insulin treatment","volume":"800","author":"Biessels","year":"1998","journal-title":"Brain Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0006-8993(02)02887-1","article-title":"Hippocampal neuronal apoptosis in type 1 diabetes","volume":"946","author":"Li","year":"2002","journal-title":"Brain Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.2337\/diabetes.54.5.1497","article-title":"The effect of C-peptide on cognitive dysfunction and hippocampal apoptosis in type 1 diabetic rats","volume":"54","author":"Sima","year":"2005","journal-title":"Diabetes"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1037\/0735-7044.112.5.1199","article-title":"Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats","volume":"112","author":"Lannert","year":"1998","journal-title":"Behav. Neurosci."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1210\/en.2009-0695","article-title":"Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes","volume":"150","author":"Kim","year":"2009","journal-title":"Endocrinology"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2337\/db07-0171","article-title":"Alzheimer-like changes in rat models of spontaneous diabetes","volume":"56","author":"Li","year":"2007","journal-title":"Diabetes"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jns.2007.01.017","article-title":"Brain mitochondrial dysfunction as a link between Alzheimer\u2019s disease and diabetes","volume":"257","author":"Moreira","year":"2007","journal-title":"J. Neurol. Sci."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.bbadis.2010.07.001","article-title":"Cortical and hippocampal mitochondria bioenergetics and oxidative status during hyperglycemia and\/or insulin-induced hypoglycemia","volume":"1802","author":"Cardoso","year":"2010","journal-title":"Biochim. Biophys. Acta."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.0022-3042.2001.00681.x","article-title":"Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities","volume":"80","author":"Casley","year":"2002","journal-title":"J. Neurochem."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1523\/JNEUROSCI.4276-04.2005","article-title":"Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42","volume":"5","author":"Crouch","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/hmg\/ddl066","article-title":"Mitochondria are a direct site of A beta accumulation in Alzheimer\u2019s disease neurons: Implications for free radical generation and oxidative damage in disease progression","volume":"15","author":"Manczak","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1096\/fj.05-3735fje","article-title":"Mitochondrial Abeta: A potential focal point for neuronal metabolic dysfunction in Alzheimer\u2019s disease","volume":"19","author":"Caspersen","year":"2005","journal-title":"FASEB J."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"9057","DOI":"10.1523\/JNEUROSCI.1469-06.2006","article-title":"Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer\u2019s disease brain is associated with mitochondrial dysfunction","volume":"26","author":"Devi","year":"2006","journal-title":"J. Neurosci."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1126\/science.1091230","article-title":"ABAD directly links Abeta to mitochondrial toxicity in Alzheimer\u2019s disease","volume":"304","author":"Lustbader","year":"2004","journal-title":"Science"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1523\/JNEUROSCI.4717-10.2011","article-title":"Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer\u2019s disease","volume":"31","author":"Yao","year":"2011","journal-title":"J. Neurosci."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1471-4159.1992.tb09439.x","article-title":"Brain cytochrome oxidase in Alzheimer\u2019s disease","volume":"59","author":"Kish","year":"1992","journal-title":"J. Neurochem."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1212\/WNL.44.6.1086","article-title":"Reduced platelet cytochrome c oxidase activity in Alzheimer\u2019s disease","volume":"44","author":"Parker","year":"1994","journal-title":"Neurology"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s007020050099","article-title":"Abnormalities of mitochondrial enzymes in Alzheimer disease","volume":"105","author":"Gibson","year":"1998","journal-title":"J. Neural. Transm."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1023\/A:1020783614031","article-title":"The expression of several mitochondrial and nuclear genes encoding the subunits of electron transport chain enzyme complexes, cytochrome c oxidase, and NADH dehydrogenase, in different brain regions in Alzheimer\u2019s disease","volume":"24","author":"Aksenov","year":"1999","journal-title":"Neurochem. Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1523\/JNEUROSCI.21-09-03017.2001","article-title":"Mitochondrial abnormalities in Alzheimer\u2019s disease","volume":"21","author":"Hirai","year":"2001","journal-title":"J. Neurosci."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0197-4580(01)00314-1","article-title":"Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer\u2019s disease","volume":"23","author":"Bosetti","year":"2002","journal-title":"Neurobiol. Aging"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.mito.2006.10.004","article-title":"Impaired platelet mitochondrial activity in Alzheimer\u2019s disease and mild cognitive impairment","volume":"6","author":"Valla","year":"2006","journal-title":"Mitochondrion"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ana.20474","article-title":"Mitochondrial abnormalities in Alzheimer brain: Mechanistic implications","volume":"57","author":"Bubber","year":"2005","journal-title":"Ann. Neurol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/jnr.10756","article-title":"Inhibition of alpha-ketoglutarate dehydrogenase complex promotes cytochrome c release from mitochondria, caspase-3 activation, and necrotic cell death","volume":"74","author":"Huang","year":"2003","journal-title":"J. Neurosci. Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"8972","DOI":"10.1523\/JNEUROSCI.20-24-08972.2000","article-title":"Inhibition of Krebs cycle enzymes by hydrogen peroxide: A key role of [alpha]-ketoglutarate dehydrogenase in limiting NADH production under oxidative stress","volume":"20","author":"Tretter","year":"2000","journal-title":"J. Neurosci."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0896-6273(02)00604-9","article-title":"Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down\u2019s syndrome","volume":"33","author":"Busciglio","year":"2002","journal-title":"Neuron"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1212\/WNL.49.4.918","article-title":"Cybrids in Alzheimer\u2019s disease: A cellular model of the disease?","volume":"49","author":"Swerdlow","year":"1997","journal-title":"Neurology"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jprot.2010.12.012","article-title":"Early dysregulation of the mitochondrial proteome in a mouse model of Alzheimer\u2019s disease","volume":"74","author":"Chou","year":"2011","journal-title":"J. Proteomics"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1471-4159.2004.02455.x","article-title":"Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice","volume":"89","author":"Li","year":"2004","journal-title":"J. Neurochem."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1083\/jcb.200207030","article-title":"Mitochondrial targeting and a novel transmembrane arrest of Alzheimer\u2019s amyloid precursor protein impairs mitochondrial function in neuronal cells","volume":"161","author":"Anandatheerthavarada","year":"2003","journal-title":"J. Cell Biol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.2337\/diabetes.51.10.2944","article-title":"Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes","volume":"51","author":"Kelley","year":"2002","journal-title":"Diabetes"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s00125-004-1627-9","article-title":"Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients","volume":"48","author":"Anello","year":"2005","journal-title":"Diabetologia"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2337\/diabetes.52.6.1449","article-title":"Increased vulnerability of brain mitochondria in diabetic (Goto-Kakizaki) rats with aging and amyloid-beta exposure","volume":"52","author":"Moreira","year":"2003","journal-title":"Diabetes"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1677\/joe.1.06269","article-title":"Oxidative and nitrosative stress in brain mitochondria of diabetic rats","volume":"187","author":"Mastrocola","year":"2005","journal-title":"J. Endocrinol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.nbd.2004.10.017","article-title":"Insulin protects against amyloid beta-peptide toxicity in brain mitochondria of diabetic rats","volume":"18","author":"Moreira","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00125-009-1553-y","article-title":"Diabetes regulates mitochondrial biogenesis and fission in mouse neurons","volume":"53","author":"Edwards","year":"2010","journal-title":"Diabetologia"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1586\/eem.09.55","article-title":"Mitochondrial stress and the pathogenesis of diabetic neuropathy","volume":"5","author":"Fernyhough","year":"2010","journal-title":"Expert. Rev. Endocrinol. Metab."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/syn.20863","article-title":"Impact of STZ-induced hyperglycemia and insulin-induced hypoglycemia in plasma amino acids and cortical synaptosomal neurotransmitters","volume":"65","author":"Cardoso","year":"2010","journal-title":"Synapse"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00702-004-0255-3","article-title":"Oxidative stress potentiates BACE1 gene expression and Abeta generation","volume":"112","author":"Tong","year":"2005","journal-title":"J. Neural. Transm."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"17721","DOI":"10.1074\/jbc.M800013200","article-title":"Hydrogen peroxide promotes Abeta production through JNK-dependent activation of gamma-secretase","volume":"283","author":"Shen","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1471-4159.2007.05072.x","article-title":"Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein","volume":"104","author":"Tamagno","year":"2008","journal-title":"J. Neurochem."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.neuint.2009.06.012","article-title":"Oxidative stress promotes JNK-dependent amyloidogenic processing of normally expressed human APP by differential modification of alpha-, beta- and gamma-secretase expression","volume":"55","author":"Rojas","year":"2009","journal-title":"Neurochem. Int."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.neurobiolaging.2008.07.003","article-title":"Evidence that gamma-secretase mediates oxidative stress-induced beta-secretase expression in Alzheimer\u2019s disease","volume":"31","author":"Jo","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jnr.22271","article-title":"Oxidative stress up-regulates presenilin 1 in lipid rafts in neuronal cells","volume":"88","author":"Oda","year":"2010","journal-title":"J. Neurosci. Res."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"S499","DOI":"10.3233\/JAD-2010-100504","article-title":"Amyloid-beta and mitochondria in aging and Alzheimer\u2019s disease: Implications for synaptic damage and cognitive decline","volume":"20","author":"Reddy","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.neurobiolaging.2005.05.005","article-title":"Oxidative modification and down-regulation of Pin1 in Alzheimer\u2019s disease hippocampus: A redox proteomics analysis","volume":"27","author":"Sultana","year":"2006","journal-title":"Neurobiol. Aging"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1046\/j.1471-4159.1997.68052092.x","article-title":"4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer\u2019s disease","volume":"68","author":"Sayre","year":"1997","journal-title":"J. Neurochem."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1523\/JNEUROSCI.17-08-02653.1997","article-title":"Widespread peroxynitrite-mediated damage in Alzheimer\u2019s disease","volume":"17","author":"Smith","year":"1997","journal-title":"J. Neurosci."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1046\/j.1471-4159.1998.71052034.x","article-title":"Increased nuclear DNA oxidation in the brain in Alzheimer\u2019s disease","volume":"71","author":"Gabbita","year":"1998","journal-title":"J. Neurochem."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/ana.410440322","article-title":"Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer\u2019s disease","volume":"44","author":"Montine","year":"1998","journal-title":"Ann. Neurol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1046\/j.1471-4159.1999.0720734.x","article-title":"F4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer\u2019s disease","volume":"72","author":"Liu","year":"1999","journal-title":"J. Neurochem."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1523\/JNEUROSCI.19-06-01959.1999","article-title":"RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer\u2019s disease","volume":"19","author":"Nunomura","year":"1999","journal-title":"J. Neurosci."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/archneur.58.3.392","article-title":"Ratio of 8-hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in Alzheimer disease ventricular cerebrospinal fluid","volume":"58","author":"Lovell","year":"2001","journal-title":"Arch. Neurol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.nbd.2004.06.003","article-title":"Neuronal RNA oxidation is a prominent feature of familial Alzheimer\u2019s disease","volume":"17","author":"Nunomura","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/jnen\/60.8.759","article-title":"Oxidative damage is the earliest event in Alzheimer disease","volume":"60","author":"Nunomura","year":"2001","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1523\/JNEUROSCI.21-12-04183.2001","article-title":"Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis","volume":"21","author":"Pratico","year":"2001","journal-title":"J. Neurosci."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.freeradbiomed.2008.03.012","article-title":"Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease","volume":"44","author":"Resende","year":"2008","journal-title":"Free Radic. Biol. Med."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ijdevneu.2004.07.006","article-title":"Aging-related increase in oxidative stress correlates with developmental pattern of beta-secretase activity and beta-amyloid plaque formation in transgenic Tg2576 mice with Alzheimer-like pathology","volume":"22","author":"Apelt","year":"2004","journal-title":"Int. J. Dev. Neurosci."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1210\/er.2003-0019","article-title":"Oxidative stress in the pathogenesis of diabetic neuropathy","volume":"25","author":"Vincent","year":"2004","journal-title":"Endocr. Rev."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/dmrr.196","article-title":"The role of oxidative stress in the onset and progression of diabetes and its complications: A summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society","volume":"17","author":"Nawroth","year":"2001","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.nbd.2008.02.013","article-title":"Oxidative injury and neuropathy in diabetes and impaired glucose tolerance","volume":"30","author":"Russell","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/382685a0","article-title":"RAGE and amyloid-beta peptide neurotoxicity in Alzheimer\u2019s disease","volume":"382","author":"Yan","year":"1996","journal-title":"Nature"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.neurobiolaging.2009.04.016","article-title":"Advanced glycation endproducts and their receptor RAGE in Alzheimer\u2019s disease","volume":"32","author":"Srikanth","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1054-3589(08)60961-8","article-title":"Advanced glycosylation: Chemistry, biology, and implications for diabetes and aging","volume":"23","author":"Bucala","year":"1992","journal-title":"Adv. Pharmacol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1042\/bj2560205","article-title":"Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing","volume":"256","author":"Hunt","year":"1988","journal-title":"Biochem. J."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0006-291X(05)80875-7","article-title":"Free radical generation by early glycation products: A mechanism for accelerated atherogenesis in diabetes","volume":"173","author":"Mullarkey","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1073\/pnas.91.12.5710","article-title":"Advanced Maillard reaction end products are associated with Alzheimer disease pathology","volume":"91","author":"Smith","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1073\/pnas.91.11.4766","article-title":"Advanced glycation end products contribute to amyloidosis in Alzheimer disease","volume":"91","author":"Vitek","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"21614","DOI":"10.1016\/S0021-9258(17)31849-5","article-title":"Analysis of microtubule-associated protein tau glycation in paired helical filaments","volume":"269","author":"Ledesma","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nm0795-693","article-title":"Non-enzymatically glycated tau in Alzheimer\u2019s disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide","volume":"1","author":"Yan","year":"1995","journal-title":"Nat. Med."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1172\/JCI116482","article-title":"Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus","volume":"91","author":"McCance","year":"1993","journal-title":"J. Clin. Investig."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3109\/07853899608999102","article-title":"Advanced glycation end-products and atherosclerosis","volume":"28","author":"Vlassara","year":"1996","journal-title":"Ann. Med."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/ndt\/11.supp5.41","article-title":"New biomarkers of Maillard reaction damage to proteins","volume":"11","author":"Brinkmann","year":"1996","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s001250051221","article-title":"Differential accumulation of advanced glycation end products in the course of diabetic retinopathy","volume":"42","author":"Hammes","year":"1999","journal-title":"Diabetologia"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1210\/jc.2007-1817","article-title":"Clinical review: The role of advanced glycation end products in progression and complications of diabetes","volume":"93","author":"Goh","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF00403972","article-title":"Diabetes mellitus and Alzheimer\u2019s disease: Glycation as a biochemical link","volume":"39","author":"Smith","year":"1996","journal-title":"Diabetologia"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/0304-3940(96)13100-1","article-title":"Early contribution of oxidative glycation in Alzheimer disease","volume":"217","author":"Smith","year":"1996","journal-title":"Neurosci. Lett."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1006\/nbdi.2001.0470","article-title":"Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains","volume":"9","author":"Wahrle","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"36815","DOI":"10.1074\/jbc.M504484200","article-title":"Lipids as modulators of proteolytic activity of BACE: Involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro","volume":"280","author":"Kalvodova","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"22529","DOI":"10.1074\/jbc.M801925200","article-title":"Direct and potent regulation of gamma-secretase by its lipid microenvironment","volume":"283","author":"Osenkowski","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s11064-006-9200-1","article-title":"Alzheimer\u2019s disease and cholesterol: The fat connection","volume":"32","author":"Canevari","year":"2007","journal-title":"Neurochem. Res."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1523\/JNEUROSCI.4315-03.2004","article-title":"Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice","volume":"24","author":"Brecht","year":"2004","journal-title":"J. Neurosci."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1146\/annurev.genom.1.1.507","article-title":"Apolipoprotein E: Far more than a lipid transport protein","volume":"1","author":"Mahley","year":"2000","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"48529","DOI":"10.1074\/jbc.M306923200","article-title":"APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response","volume":"278","author":"Lynch","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/nature04001","article-title":"Apolipoprotein-mediated pathways of lipid antigen presentation","volume":"437","author":"Garg","year":"2005","journal-title":"Nature"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev.med.47.1.387","article-title":"Apolipoprotein E alleles as risk factors in Alzheimer\u2019s disease","volume":"47","author":"Roses","year":"1996","journal-title":"Annu. Rev. Med."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nrn2494","article-title":"Thirty years of Alzheimer\u2019s disease genetics: The implications of systematic meta-analyses","volume":"9","author":"Bertram","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/1531-8249(200009)48:3<297::AID-ANA3>3.0.CO;2-Z","article-title":"Mitochondrial damage in Alzheimer\u2019s disease varies with apolipoprotein E genotype","volume":"48","author":"Gibson","year":"2000","journal-title":"Ann. Neurol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/ncb1001-905","article-title":"Acyl-coenzyme A: Cholesterol acyltransferase modulates the generation of the amyloid beta-peptide","volume":"3","author":"Puglielli","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1016\/j.neurobiolaging.2015.04.002","article-title":"Acyl-coenzyme A: Cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer\u2019s disease mouse and reduces human P301L-tau content at the presymptomatic stage","volume":"36","author":"Shibuya","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.neuron.2004.08.043","article-title":"The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer\u2019s disease","volume":"44","author":"Huttunen","year":"2004","journal-title":"Neuron"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.bbalip.2010.04.003","article-title":"ACAT inhibition and amyloid beta reduction","volume":"1801","author":"Bhattacharyya","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1073\/pnas.0913828107","article-title":"ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD","volume":"107","author":"Bryleva","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"6460","DOI":"10.1073\/pnas.95.11.6460","article-title":"Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons","volume":"95","author":"Simons","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1073\/pnas.1018381108","article-title":"C-terminal-truncated apolipoprotein (apo) E4 inefficiently clears amyloid-beta (Abeta) and acts in concert with Abeta to elicit neuronal and behavioral deficits in mice","volume":"108","author":"Xu","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"10966","DOI":"10.1073\/pnas.1434398100","article-title":"Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer\u2019s disease-like neurodegeneration and behavioral deficits in transgenic mice","volume":"100","author":"Harris","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_229","doi-asserted-by":"crossref","unstructured":"Castellano, J.M., Kim, J., Stewart, F.R., Jiang, H., DeMattos, R.B., Patterson, B.W., Fagan, A.M., Morris, J.C., Mawuenyega, K.G., and Cruchaga, C. (2011). Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci. Transl. Med., 3.","DOI":"10.1126\/scitranslmed.3002156"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"10914","DOI":"10.1073\/pnas.95.18.10914","article-title":"Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females","volume":"95","author":"Raber","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/35006165","article-title":"Apolipoprotein E and cognitive performance","volume":"404","author":"Raber","year":"2000","journal-title":"Nature"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.2337\/diabetes.51.4.1256","article-title":"Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia aging study","volume":"51","author":"Peila","year":"2002","journal-title":"Diabetes"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1007\/s001250050822","article-title":"NIDDM as a disease of the innate immune system: Association of acute-phase reactants and interleukin-6 with metabolic syndrome X","volume":"40","author":"Pickup","year":"1997","journal-title":"Diabetologia"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"812","DOI":"10.2337\/diabetes.52.3.812","article-title":"Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study","volume":"52","author":"Spranger","year":"2003","journal-title":"Diabetes"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1055\/s-2005-858252","article-title":"Inflammation and type 2 diabetes: Results from KORA Augsburg","volume":"67","author":"Herder","year":"2005","journal-title":"Gesundheitswesen"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2337\/dc08-1161","article-title":"Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: The Whitehall II study","volume":"32","author":"Herder","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1172\/JCI200215318","article-title":"Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets","volume":"110","author":"Maedler","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"8138","DOI":"10.1073\/pnas.0305683101","article-title":"Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets","volume":"101","author":"Maedler","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.2337\/db06-1650","article-title":"Increased number of islet-associated macrophages in type 2 diabetes","volume":"56","author":"Ehses","year":"2007","journal-title":"Diabetes"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","article-title":"Inflammation and Alzheimer\u2019s disease","volume":"21","author":"Akiyama","year":"2000","journal-title":"Neurobiol. Aging"},{"key":"ref_241","unstructured":"Lee, S., Tong, M., Hang, S., Deochand, C., and de la Monte, S.M. (2013). CSF and brain indices of insulin resistance, oxidative stress and neuro-inflammation in early versus late Alzheimer\u2019s disease. J. Alzheimers Dis. Parkinsonism, 3."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.arr.2005.06.006","article-title":"Harnessing the power of gene microarrays for the study of brain aging and Alzheimer\u2019s disease: Statistical reliability and functional correlation","volume":"4","author":"Blalock","year":"2005","journal-title":"Ageing Res. Rev."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0074-7742(05)63003-6","article-title":"Large-scale microarray studies of gene expression in multiple regions of the brain in schizophrenia and Alzheimer\u2019s disease","volume":"63","author":"Katsel","year":"2005","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/01.jnen.0000178444.33972.e0","article-title":"Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: Implications for Alzheimer therapeutics","volume":"64","author":"Morgan","year":"2005","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_245","doi-asserted-by":"crossref","unstructured":"Heneka, M.T., Sastre, M., Dumitrescu-Ozimek, L., Dewachter, I., Walter, J., Klockgether, T., and Van Leuven, F. (2005). Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J. Neuroinflamm., 2.","DOI":"10.1186\/1742-2094-2-22"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"8843","DOI":"10.1523\/JNEUROSCI.2868-05.2005","article-title":"Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer\u2019s disease","volume":"25","author":"Kitazawa","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000078501","article-title":"Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer\u2019s disease: A systematic review","volume":"23","author":"Szekely","year":"2004","journal-title":"Neuroepidemiology"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1212\/WNL.54.3.588","article-title":"A randomized controlled trial of prednisone in Alzheimer\u2019s disease. Alzheimer\u2019s Disease Cooperative Study","volume":"54","author":"Aisen","year":"2000","journal-title":"Neurology"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","article-title":"Effects of rofecoxib or naproxen vs. placebo on Alzheimer disease progression: A randomized controlled trial","volume":"289","author":"Aisen","year":"2003","journal-title":"JAMA"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(01)05623-9","article-title":"Effect of hydroxychloroquine on progression of dementia in early Alzheimer\u2019s disease: An 18-month randomised, double-blind, placebo-controlled study","volume":"358","author":"Weinstein","year":"2001","journal-title":"Lancet"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1212\/WNL.62.1.66","article-title":"Rofecoxib: No effect on Alzheimer\u2019s disease in a 1-year, randomized, blinded, controlled study","volume":"62","author":"Reines","year":"2004","journal-title":"Neurology"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1096\/fj.06-7703com","article-title":"Amyloid beta oligomers induce impairment of neuronal insulin receptors","volume":"22","author":"Zhao","year":"2008","journal-title":"FASEB J."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejphar.2004.02.045","article-title":"Insulin and the insulin receptor in experimental models of learning and memory","volume":"490","author":"Zhao","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1037\/a0017722","article-title":"Intracerebroventricular insulin improves spatial learning and memory in male Wistar rats","volume":"123","author":"Mohaddes","year":"2009","journal-title":"Behav. Neurosci."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1093\/brain\/awn288","article-title":"Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy","volume":"131","author":"Francis","year":"2008","journal-title":"Brain"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1474-4422(08)70021-8","article-title":"Cognition and diabetes: A lifespan perspective","volume":"7","author":"Biessels","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2337\/diacare.28.3.726","article-title":"The effects of type 1 diabetes on cognitive performance: A meta-analysis","volume":"28","author":"Brands","year":"2005","journal-title":"Diabetes Care"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1210\/er.2007-0034","article-title":"Cognitive dysfunction and diabetes melli- tus","volume":"29","author":"Kodl","year":"2008","journal-title":"Endocr. Rev."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.psyneuen.2004.04.003","article-title":"Intranasal insulin improves memory in humans","volume":"29","author":"Benedict","year":"2004","journal-title":"Psychoneuroendocrinology"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1210\/jc.2007-2606","article-title":"Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin","volume":"93","author":"Benedict","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/sj.npp.1301193","article-title":"Intranasal insulin improves memory in humans: Superiority of insulin aspart","volume":"32","author":"Benedict","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"E468","DOI":"10.1210\/jc.2010-0744","article-title":"Comparable sensitivity of postmenopausal and young women to the effects of intranasal insulin on food intake and working memory","volume":"95","author":"Krug","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.neurobiolaging.2005.03.016","article-title":"Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype","volume":"27","author":"Reger","year":"2006","journal-title":"Neurobiol. Aging"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/00325481.1977.11714510","article-title":"CNS manifestations of diabetes mellitus","volume":"61","author":"DeJong","year":"1977","journal-title":"Postgrad. Med."},{"key":"ref_265","first-page":"273","article-title":"Diabetic encephalopathy. Diffuse and focal lesions of the brain in long-term diabetes","volume":"39","author":"Lundbaek","year":"1963","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ejphar.2004.02.054","article-title":"The relationship between type 2 diabetes and cognitive dysfunction: Longitudinal studies and their methodological limitations","volume":"490","author":"Allen","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bbadis.2008.12.003","article-title":"(Pre)diabetes, brain aging, and cognition","volume":"1792","author":"Rosset","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrn3209","article-title":"The many faces of insulin- like peptide signalling in the brain","volume":"13","author":"Fernandez","year":"2012","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_269","first-page":"261","article-title":"Insulin-like growth factor-1 (IGF-1): A neuroprotective trophic factor acting via the Akt kinase pathway","volume":"60","author":"Zheng","year":"2000","journal-title":"J. Neural. Transm. Suppl."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1749-6632.1999.tb08015.x","article-title":"Protective and rescuing abilities of IGF-I and some putative free radical scavengers against beta-amyloid-inducing toxicity in neurons","volume":"890","author":"Dore","year":"1999","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1073\/pnas.94.9.4772","article-title":"Insulin-like growth factor I protects and rescues hippocampal neurons against beta-amyloid- and human amylin-induced toxicity","volume":"94","author":"Dore","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0196-9781(02)00063-3","article-title":"Biogenesis and metabolism of Alzheimer\u2019s disease Abeta amyloid peptides","volume":"23","author":"Evin","year":"2002","journal-title":"Peptides"},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jnr.10703","article-title":"Characterization of the toxic mechanism triggered by Alzheimer\u2019s amyloid-beta peptides via p75 neurotrophin receptor in neuronal hybrid cells","volume":"73","author":"Tsukamoto","year":"2003","journal-title":"J. Neurosci. Res."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1210\/en.2012-1661","article-title":"Insulin has multiple antiamyloidogenic effects on human neuronal cells","volume":"154","author":"Pandini","year":"2012","journal-title":"Endocrinology"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1212\/01.WNL.0000065916.25128.25","article-title":"Insulin increases CSF Abeta42 levels in normal older adults","volume":"60","author":"Watson","year":"2003","journal-title":"Neurology"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2337\/dc11-2075","article-title":"Impaired insulin sensitivity as indexed by the HOMA score is associated with deficits in verbal fluency and temporal lobe gray matter volume in the elderly","volume":"35","author":"Benedict","year":"2012","journal-title":"Diabetes Care"},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI59903","article-title":"Demonstrated brain insulin resistance in Alzheimer\u2019s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline","volume":"122","author":"Talbot","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI57256","article-title":"An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer\u2019s disease\u2014Associated Abeta oligomers","volume":"22","author":"Bomfim","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.neurobiolaging.2012.06.006","article-title":"Fasting plasma insulin and the default mode network in women at risk for Alzheimer\u2019s disease","volume":"34","author":"Kenna","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1471-4159.2005.03576.x","article-title":"The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice","volume":"96","author":"Asai","year":"2006","journal-title":"J. Neurochem."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"8898","DOI":"10.1523\/JNEUROSCI.2693-05.2005","article-title":"Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer\u2019s disease","volume":"25","author":"Comery","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1038\/475S9a","article-title":"Drugs: A tangled web of targets","volume":"475","author":"Gravitz","year":"2011","journal-title":"Nature"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of Abeta42 immunisation in Alzheimer\u2019s disease: Follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archneur.61.1.82","article-title":"Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County Study","volume":"61","author":"Zandi","year":"2004","journal-title":"Arch. Neurol."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1212\/01.wnl.0000244346.08950.64","article-title":"A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease","volume":"67","author":"Aisen","year":"2006","journal-title":"Neurology"},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1212\/WNL.53.1.197","article-title":"A double-blind, placebo-controlled trial of diclofenac\/misoprostol in Alzheimer\u2019s disease","volume":"53","author":"Scharf","year":"1999","journal-title":"Neurology"},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2174\/156720508783884576","article-title":"Memantine treatment in patients with mild to moderate Alzheimer\u2019s disease already receiving a cholinesterase inhibitor: A randomized, double-blind, placebo-controlled trial","volume":"5","author":"Porsteinsson","year":"2008","journal-title":"Curr. Alzheimer Res."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.2337\/db14-0287","article-title":"Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease","volume":"63","author":"Yarchoan","year":"2014","journal-title":"Diabetes"},{"key":"ref_292","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2013). Standards of medical care in diabetes\u20132013. Diabetes Care, 36, S11\u2013S66.","DOI":"10.2337\/dc13-S011"},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"9287","DOI":"10.1523\/JNEUROSCI.3348-08.2008","article-title":"Complete rescue of cerebrovascular function in aged Alzheimer\u2019s disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist","volume":"28","author":"Nicolakakis","year":"2008","journal-title":"J. Neurosci."},{"key":"ref_294","first-page":"950","article-title":"Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: A preliminary study","volume":"13","author":"Watson","year":"2005","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.jalz.2009.07.079","article-title":"Effects of rosiglitazone-extended release as adjunctive therapy to acetylcholinesterase inhibitors over 48 weeks on cognition in Apoe4-stratified subjects with mild-to-moderate Alzheimer\u2019s disease","volume":"5","author":"Harrington","year":"2009","journal-title":"Alzheimer Dement."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1210\/en.2007-1553","article-title":"Peroxisome proliferatoractivated receptor-gamma-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status","volume":"149","author":"Festuccia","year":"2008","journal-title":"Endocrinology"},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1089\/ars.2010.3816","article-title":"Cortical neurons develop insulin resistance and blunted Akt signaling: A potential mechanism contributing to enhanced ischemic injury in diabetes","volume":"14","author":"Kim","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1734-1140(10)70357-1","article-title":"Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide","volume":"62","author":"Suchy","year":"2010","journal-title":"Pharmacol. Rep."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.4049\/jimmunol.0803563","article-title":"Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis","volume":"182","author":"Nath","year":"2009","journal-title":"J. Immunol."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuropharm.2011.01.033","article-title":"Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer\u2019s-like changes","volume":"60","author":"Gupta","year":"2011","journal-title":"Neuropharmacology"},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1073\/pnas.0807991106","article-title":"Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer\u2019s amyloid peptides via up-regulating BACE1 transcription","volume":"106","author":"Chen","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2174\/1389450043345245","article-title":"A new Alzheimer\u2019s disease interventive strategy: GLP-1","volume":"5","author":"Perry","year":"2004","journal-title":"Curr. Drug Targets"},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","article-title":"The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease","volume":"31","author":"McClean","year":"2011","journal-title":"J. Neurosci."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0306-4522(02)00162-8","article-title":"Impairment of longterm potentiation and spatial memory in leptin receptor-deficient rodents","volume":"113","author":"Li","year":"2002","journal-title":"Neuroscience"},{"key":"ref_305","doi-asserted-by":"crossref","unstructured":"Paz-Filho, G.J., Babikian, T., Asarnow, R., Delibasi, T., Esposito, K., Erol, H.K., Wong, M.L., and Licinio, J. (2008). Leptin replacement improves cognitive development. PLoS ONE, 3.","DOI":"10.1371\/annotation\/df013c27-a849-4ce6-990b-e6cad0d95fea"},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3233\/JAD-2010-1308","article-title":"Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer\u2019s disease","volume":"19","author":"Greco","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1001\/jama.2009.1836","article-title":"Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging","volume":"302","author":"Lieb","year":"2009","journal-title":"JAMA"},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.neurobiolaging.2013.10.076","article-title":"Neuroprotective effects of the amylin analogue pramlintide on Alzheimer\u2019s disease pathogenesis and cognition","volume":"35","author":"Adler","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/oby.2009.184","article-title":"Enhanced weight loss with pramlintide\/metreleptin: An integrated neurohormonal approach to obesity pharmacotherapy","volume":"17","author":"Ravussin","year":"2009","journal-title":"Obesity"},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0301-0082(91)90015-S","article-title":"Insulin receptors in the central nervous system: Localization, signalling mechanisms and functional aspects","volume":"36","author":"Unger","year":"1991","journal-title":"Prog. Neurobiol."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1172\/JCI116773","article-title":"Saturable transport of insulin from plasma into the central nervous system of dogs in vivo. A mechanism for regulated insulin delivery to the brain","volume":"92","author":"Baura","year":"1993","journal-title":"J. Clin. Invest."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.2337\/diabetes.53.9.2202","article-title":"Transcortical direct current potential shift reflects immediate signaling of systemic insulin to the human brain","volume":"53","author":"Hallschmid","year":"2004","journal-title":"Diabetes"},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"6734","DOI":"10.1523\/JNEUROSCI.1350-09.2009","article-title":"Awake intranasal insulin delivery modifies protein complexes and alters memory, anxiety, and olfactory behaviors","volume":"29","author":"Marks","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.addr.2007.08.019","article-title":"Current challenges in non-invasive insulin delivery systems: A comparative review","volume":"59","author":"Khafagy","year":"2007","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/dmrr.397","article-title":"Intranasally administered insulin intended for prevention of type 1 diabetes\u2014a safety study in healthy adults","volume":"19","author":"Kupila","year":"2003","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3233\/JAD-141791","article-title":"Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer\u2019s disease dementia","volume":"44","author":"Claxton","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.neurobiolaging.2004.11.011","article-title":"Insulin effects on CSF norepinephrine and cognition in Alzheimer\u2019s disease","volume":"27","author":"Watson","year":"2006","journal-title":"Neurobiol. Aging"},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1155\/NP.2005.311","article-title":"The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer\u2019s disease","volume":"12","author":"Messier","year":"2005","journal-title":"Neural. Plast."},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1212\/WNL.60.12.1886","article-title":"Insulin and Alzheimer\u2019s disease: An amyloid connection","volume":"60","author":"Galasko","year":"2003","journal-title":"Neurology"},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.metabol.2005.04.026","article-title":"Immediate but not long-term intranasal administration of insulin raises blood pressure in human beings","volume":"54","author":"Benedict","year":"2005","journal-title":"Metabolism"},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archneurol.2011.233","article-title":"Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial","volume":"69","author":"Craft","year":"2012","journal-title":"Arch. Neurol."},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1212\/01.wnl.0000344246.91081.2c","article-title":"Intranasal insulin improves cognition and modulates beta-amyloid in early AD","volume":"72","author":"Dhamoon","year":"2009","journal-title":"Neurology"},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1212\/01.WNL.0000265401.62434.36","article-title":"Intranasal insulin improves cognition and modulates beta-amyloid in early AD","volume":"70","author":"Reger","year":"2008","journal-title":"Neurology"},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s12035-011-8229-6","article-title":"Brain insulin signaling and Alzheimer\u2019s disease: Current evidence and future directions","volume":"46","author":"Schioth","year":"2012","journal-title":"Mol. Neurobiol."},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1210\/jc.2011-1802","article-title":"Effect of intranasal insulin on cognitive function: A systematic review","volume":"97","author":"Shemesh","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2337\/db14-0685","article-title":"Intranasal insulin suppresses endogenous glucose production in humans compared with placebo in the presence of similar venous insulin concentrations","volume":"64","author":"Dash","year":"2005","journal-title":"Diabetes"},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.2337\/db14-0892","article-title":"Effects of intranasal insulin on hepatic fat accumulation and energy metabolism in humans","volume":"64","author":"Gancheva","year":"2015","journal-title":"Diabetes"},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nn0602-849","article-title":"Sniffing neuropeptides: A transnasal approach to the human brain","volume":"5","author":"Born","year":"2002","journal-title":"Nat. Neurosci."},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.regpep.2007.06.012","article-title":"Towards the therapeutic use of intranasal neuropeptide administration in metabolic and cognitive disorders","volume":"149","author":"Hallschmid","year":"2008","journal-title":"Regul. Pept."},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1073858410381532","article-title":"Sink hypothesis and therapeutic strategies for attenuating Abeta levels","volume":"17","author":"Zhang","year":"2011","journal-title":"Neuroscientist"},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/S0168-8227(11)70013-4","article-title":"Insulin sensitivity of the human brain","volume":"93","author":"Ketterer","year":"2011","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1038\/sj.ijo.0802746","article-title":"Engineering predictability and protraction in a basal insulin analogue: The pharmacology of insulin detemir","volume":"28","author":"Kurtzhals","year":"2004","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1463-1326.2004.00363.x","article-title":"Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin","volume":"7","author":"Vague","year":"2005","journal-title":"Diabetes Obes. Metab."},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.addr.2004.07.011","article-title":"Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics","volume":"56","author":"Shen","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1463-1326.2008.00976.x","article-title":"Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis","volume":"11","author":"Monami","year":"2009","journal-title":"Diabetes. Obes. Metab."},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1007\/s00125-006-0192-9","article-title":"Tissue selectivity of insulin detemir action in vivo","volume":"49","author":"Hennige","year":"2006","journal-title":"Diabetologia"},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.2337\/db09-1493","article-title":"Euglycemic infusion of insulin detemir compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects","volume":"59","author":"Hallschmid","year":"2010","journal-title":"Diabetes"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/21\/6\/689\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:24:32Z","timestamp":1760210672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/21\/6\/689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,26]]},"references-count":337,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,6]]}},"alternative-id":["molecules21060689"],"URL":"https:\/\/doi.org\/10.3390\/molecules21060689","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,26]]}}}